CN109646438A - The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug - Google Patents
The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug Download PDFInfo
- Publication number
- CN109646438A CN109646438A CN201811591052.5A CN201811591052A CN109646438A CN 109646438 A CN109646438 A CN 109646438A CN 201811591052 A CN201811591052 A CN 201811591052A CN 109646438 A CN109646438 A CN 109646438A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- hydrochloride
- application according
- demethyl coclaurine
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- WZRCQWQRFZITDX-UHFFFAOYSA-N (RS)-norcoclaurine Chemical compound C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-UHFFFAOYSA-N 0.000 title claims abstract description 18
- WZRCQWQRFZITDX-AWEZNQCLSA-N Norcoclaurine Natural products C1=CC(O)=CC=C1C[C@H]1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-AWEZNQCLSA-N 0.000 title claims abstract description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 12
- 201000010105 allergic rhinitis Diseases 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229940100688 oral solution Drugs 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 210000003097 mucus Anatomy 0.000 claims description 3
- 229940042126 oral powder Drugs 0.000 claims description 3
- 230000001314 paroxysmal effect Effects 0.000 claims description 3
- 210000003800 pharynx Anatomy 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229940023488 pill Drugs 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 229960003088 loratadine Drugs 0.000 abstract description 5
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 description 13
- 108010058846 Ovalbumin Proteins 0.000 description 11
- 229940092253 ovalbumin Drugs 0.000 description 11
- -1 small molecule compound Chemical class 0.000 description 9
- 210000001331 nose Anatomy 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010041232 sneezing Diseases 0.000 description 3
- LVVKXRQZSRUVPY-HNNXBMFYSA-N (S)-coclaurine Chemical compound C([C@@H]1NCCC=2C=C(C(=CC=21)O)OC)C1=CC=C(O)C=C1 LVVKXRQZSRUVPY-HNNXBMFYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses the application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug, the present invention is found to have novelty to demethyl coclaurine or its hydrochloric acid salts for treating rhinitis, it is tested by rat rhinitis models, using Loratadine as control, it was demonstrated that the curative effect of demethyl coclaurine or its hydrochloride is clear.
Description
Technical field
The present invention relates to field of medicaments, especially demethyl coclaurine or the new applications of its hydrochloride.
Background technique
Rhinitis is common clinical and frequently-occurring disease, is to contact schneiderian membrane chronic inflammation caused by allergen as susceptible individual,
Its morbidity is related with body specific mechanism disorder.Belong to the scope of immune inflammation.The drug that clinic is used to treat rhinitis has
Glucocorticoid, antihistamine, leukotriene receptor antagonists, decongestant, mast cell stabilizers etc..It most passes through at present
The medicinal treatment being often used is oral H1 antihistamine and intranasal application corticosteroid.These drugs can single use, can also
It is used in combination, there is limitation in terms of its validity.Antihistamine is only capable of alleviating Rhinitis Symptoms and cannot alleviating rhinitis and draw
The nasal congestion symptom risen；Steroids is unable to rapid relief of symptoms, and is not suitable for certain patients (especially child), may cause nose
Chamber stimulation, bleeding can even cause systemic side effects in the rare cases.Therefore, definite ingredients, quality controllable and safety are high
The small molecule compound of effect has potential value in terms of developing treatment of rhinitis drug.
In recent years, natural products class drug is considered as a kind of new therapeutic strategy for preventing and treating inflammatory disease.It goes
First coclaurine is traditionally used as cardiostimulator and anti-inflammatory agent in oriental countries.Studies have shown that demethyl coclaurine passes through reduction
The adherency of blood platelet pair, inhibits the effect of iNOS expression, and the expression of regulating up HO-1 in many cardiovascular diseases there is protection to make
With.In addition, some researches show that demethyl coclaurines immunoregulatory effect in the treatment to spinal cord injury.But according to existing salt
The research of sour demethyl coclaurine does not find it with the active report of anti-rhinitis.
Summary of the invention
Nose is treated in preparation to solve the above problems, the object of the present invention is to provide demethyl coclaurines or its hydrochloride
Application in scorching drug.
The object of the present invention is achieved like this: demethyl coclaurine or its hydrochloride answering in preparation treatment rhinitis drug
With shown in demethyl coclaurine structure such as formula (I):
Higenamine hydrochloride formula is such as shown in (II)
The rhinitis is allergic rhinitis.
The rhinitis is allergic rhinitis caused by antigen.
The symptom of the rhinitis includes: that paroxysmal continuously coughs, has a stuffy nose, rhiocnesmus, clear water sample nasal mucus, pharynx is itched, eye is itched, is coughed
Or at least one of asthma.
The drug includes at least one of demethyl coclaurine or Higenamine hydrochloride and pharmaceutically acceptable
Carrier or customary adjuvant.
The dosage form of the drug includes injection type and peroral dosage form.The injection type is preferably liquid drugs injection, spindle
Agent or powder-injection；The peroral dosage form is preferably tablet, capsule, granule, dripping pill, oral solution or powder.
Beneficial effects of the present invention:
Present invention discover that the purposes of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug belong to it is first public,
With novelty.Use Loratadine as control, Higenamine hydrochloride 60mg/kg oral administration, to antigen (ovalbumin)
Caused rat scratching nose, sneezing reaction are inhibited, and curative effect is clear, therefore, can be used for preparing the medicine for the treatment of rhinitis
Object, while there is significant progress for the prevention and treatment of rhinitis.
The present invention is described in further detail by the following examples, but protection scope of the present invention is not by specific reality
Any restrictions of example are applied, but are defined in the claims.
Specific embodiment
The object of the present invention is achieved like this: demethyl coclaurine or its hydrochloride answering in preparation treatment rhinitis drug
With shown in demethyl coclaurine structure such as formula (I):
Higenamine hydrochloride formula is such as shown in (II)
The rhinitis is allergic rhinitis, for example, allergic rhinitis caused by antigen.The symptom of rhinitis includes: paroxysmal
Continuous cough, nasal obstruction, rhiocnesmus, clear water sample nasal mucus sample, pharynx is itched, eye is itched, is coughed or at least one of asthma.
The drug includes at least one of demethyl coclaurine or Higenamine hydrochloride and pharmaceutically acceptable
Carrier or customary adjuvant.The dosage form of drug includes injection type and peroral dosage form.The injection type be preferably liquid drugs injection,
Spindle agent or powder-injection；The peroral dosage form is preferably tablet, capsule, granule, dripping pill, oral solution or powder.
The present invention is described in further detail by the following examples, but protection scope of the present invention is not by specific reality
Any restrictions of example are applied, but are defined in the claims.
Compound Higenamine hydrochloride involved in the present invention can be prepared voluntarily or for commercial product, in following embodiment
Higenamine hydrochloride is purchased from Shanghai Yuan Ye Biotechnology Co., Ltd, lot number are as follows: N 09A7C12739
Embodiment 1: the preparation of compound Higenamine hydrochloride tablet involved in the present invention:
200 g of compound Higenamine hydrochlorides are taken, addition prepares 300 grams of customary adjuvant such as dextrin, starch of tablet etc.,
It mixes, Conventional compression is made 1000.
Embodiment 2: the preparation of compound Higenamine hydrochloride capsule involved in the present invention
200 g of compound Higenamine hydrochlorides are taken, addition prepares such as 300 grams of starch of customary adjuvant of capsule, it mixes,
It is encapsulated to be made 1000.
Embodiment 3: the preparation of compound Higenamine hydrochloride oral solution involved in the present invention
20g Higenamine hydrochloride is taken, conventional solubilizer such as Tween-80 etc. is added, after the dissolution of 400ml distilled water, then plus
Suitable distilled water makes full dose at 1000ml, packing to get.
Embodiment 4: the preparation of compound Higenamine hydrochloride liquid drugs injection involved in the present invention
According to a conventional method, by Higenamine hydrochloride be prepared into it is sterile, without heat source, clear and bright no-sundries, isotonic, pH value and blood
Liquid phase etc. or it is close, safety (not haemolysis, non-sensitization) and the liquid drugs injection of stable different size.
Embodiment 5: the preparation of compound Higenamine hydrochloride lyophilized injection involved in the present invention
Sterile Higenamine hydrochloride aqueous solution is fitted into ampoule bottle or other suitable containers, in aseptic condition
Under, it is freeze-dried to be prepared into Higenamine hydrochloride freeze-dried powder, face the used time with solvent appropriate dissolution use.
Its pharmaceutical activity is further illustrated below by pharmacodynamic experiment.
Experimental example (influence that Higenamine hydrochloride of the present invention causes rat allergic rhinitis to ovalbumin)
Male SD rat, 180~220g of weight, using 0.3mg ovalbumin as antigen, 30mg aluminium-hydroxide powder conduct
Adjuvant is dissolved in 1mL physiological saline and homogenous suspension is made, to rats by intraperitoneal injection, the next day 1 time, totally 7 times, for basic sensitization.From
From low 14 days, 5% ovalbumin normal saline solution, every side 50 μ L, continuous 7d are instilled in the nasal cavity of rat two sides daily.Last
Sneezing, runny nose in rat 30min are observed after collunarium and scratch nose state.Take Loratadine successive administration 10 days, during administration every
Its collunarium persistently stimulates；Tablet made from Example 1 is configured to the solution of various concentration, and successive administration 10 days, during administration
Collunarium persistently stimulates every other day.Last time instils first 1 hour to take orally and give in ovalbumin last.
The Higenamine hydrochloride of the present invention of table 1 causes the influence (x ± SD) of rat allergic rhinitis to ovalbumin
Compared with blank group, ###P < 0.001##P < 0.01#P < 0.05
Compared with model group, * * * P < 0.001**P < 0.01*P < 0.05
Seen from table 1, Higenamine hydrochloride high dose group can obviously inhibit allergic rhinitis rat caused by ovalbumin
Sneeze and scratching nose reaction.Significant inhibiting effect is also presented in Loratadine.
The Higenamine hydrochloride of the present invention of table 2 to ovalbumin cause in the rat blood serum of rat allergic rhinitis histamine and
The influence (x ± SD) of IgE
Compared with blank group, ###P < 0.001##P < 0.01#P < 0.05
Compared with model group, * * * P < 0.001**P < 0.01*P < 0.05
As can be seen from Table 2, Higenamine hydrochloride high dose group can obviously reduce allergic rhinitis rat caused by ovalbumin
The content of histamine and IgE in serum.Loratadine also has obvious action.
Conclusion: Higenamine hydrochloride oral administration, to the scratching of rat caused by antigen (ovalbumin) amine nose, sneezing
It reacts inhibited, while can obviously reduce containing for histamine and IgE in allergic rhinitis rat blood serum caused by ovalbumin
Amount.Therefore, it can be used for preparing the drug for the treatment of rhinitis.
Claims (7)
1. the application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug, demethyl coclaurine structure such as formula (I) institute
Show:
Shown in Higenamine hydrochloride such as formula (II)
2. application according to claim 1, it is characterised in that: the rhinitis is allergic rhinitis.
3. application according to claim 1, it is characterised in that: the rhinitis is allergic rhinitis caused by antigen.
4. application according to claim 1, it is characterised in that: the symptom of rhinitis include: paroxysmal continuously cough, have a stuffy nose,
Rhiocnesmus, clear water sample nasal mucus sample, pharynx is itched, eye is itched, is coughed or at least one of asthma.
5. application according to claim 1, it is characterised in that: the drug includes that demethyl coclaurine or hydrochloric acid go first black
At least one of medicine alkali and pharmaceutically acceptable carrier or customary adjuvant.
6. application according to claim 1, it is characterised in that: the dosage form of drug includes injection type and peroral dosage form.
7. application according to claim 6, it is characterised in that: the injection type is liquid drugs injection, spindle agent or powder needle
Agent；The peroral dosage form is tablet, capsule, granule, dripping pill, oral solution or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811591052.5A CN109646438A (en) | 2018-12-25 | 2018-12-25 | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811591052.5A CN109646438A (en) | 2018-12-25 | 2018-12-25 | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109646438A true CN109646438A (en) | 2019-04-19 |
Family
ID=66116182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811591052.5A Pending CN109646438A (en) | 2018-12-25 | 2018-12-25 | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109646438A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024092959A1 (en) * | 2022-10-31 | 2024-05-10 | 深圳先进技术研究院 | Use of coclaurine and derivative thereof in improving nampt activity and pharmaceutical composition |
| CN118121605A (en) * | 2024-02-28 | 2024-06-04 | 中国科学院武汉病毒研究所 | Application of norlinderane in prevention and treatment of novel coronavirus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009073748A (en) * | 2007-09-19 | 2009-04-09 | Noevir Co Ltd | Antiallergic agent |
-
2018
- 2018-12-25 CN CN201811591052.5A patent/CN109646438A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009073748A (en) * | 2007-09-19 | 2009-04-09 | Noevir Co Ltd | Antiallergic agent |
Non-Patent Citations (1)
| Title |
|---|
| 苏宗柳 等: "温肺止流丹加减治疗变应性鼻炎56例疗效观察", 《中国民间疗法》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024092959A1 (en) * | 2022-10-31 | 2024-05-10 | 深圳先进技术研究院 | Use of coclaurine and derivative thereof in improving nampt activity and pharmaceutical composition |
| CN118121605A (en) * | 2024-02-28 | 2024-06-04 | 中国科学院武汉病毒研究所 | Application of norlinderane in prevention and treatment of novel coronavirus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111481501A (en) | Ketorolac tromethamine injection capable of reducing irritation and free of organic solvent | |
| WO2023241662A1 (en) | Compound paracetamol and chlorphenamine maleate granule and process for preparing same | |
| WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
| CN109646438A (en) | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug | |
| Awad et al. | Liquid dosage forms | |
| JP2014524478A (en) | Treatment of symptoms related to female stomach failure | |
| RU2237475C1 (en) | Combined preparation to remove symptoms of catarrhal diseases and grippe (variants) | |
| CN105919991A (en) | Application of euparin to preparation of medicine for treating depression | |
| CN109528708A (en) | Application of the Kaempferol in preparation treatment rhinitis drug | |
| CN103635194B (en) | Be used for the treatment of the pharmaceutical composition of premature ejaculation and be used for the treatment of the method for premature ejaculation | |
| CN102485242B (en) | Chinese medicinal composition for dispelling wind, clearing heat, removing toxins, and benefiting throat, and preparation method thereof | |
| CN113521057B (en) | Blood sugar reducing composition containing genistein and application thereof | |
| CN101732301A (en) | Application of chlorogenic acid in preparing medicines for preventing and curing senile dementia | |
| CN115968284A (en) | Sodium butyrate for the prevention or treatment of rhinovirus infection | |
| CN113476438B (en) | Hypoglycemic composition containing dihydromorin and its application | |
| CN112076310A (en) | A kind of pharmaceutical composition for treating multiple sclerosis and preparation thereof | |
| CN106692039B (en) | Agomelatine oral liquid preparation and preparation method and application thereof | |
| CN116531326B (en) | Oral emulsion of apremilast and preparation method thereof | |
| CN108938628A (en) | A kind of composition and its application with anti-malarial activity | |
| WO2003090749A1 (en) | Use of berberine with high solubility in preparation of medicament | |
| US9186363B1 (en) | Pharmaceutical composition and method for treating age-related macular degeneration | |
| RU2426531C1 (en) | Liquid water pharmaceutical composition of ambroxol and pharmaceutical preparation based on it, intended for treating diseases of respiratory ways with formation of viscous sputum (versions) | |
| UA145352U (en) | READY-MADE MEDICINAL PRODUCT FOR SYMPTOMATIC TREATMENT OR PREVENTION OF COLD OR FLU | |
| AU2023222825A1 (en) | Medication | |
| CN101623265B (en) | Production process for dexamethasone sodium phosphate bulk medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |
|
| RJ01 | Rejection of invention patent application after publication |